Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04974723 · ClinicalTrials.gov registry record
Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women
A clinical trial, sponsored by Radius Health.
- Completed
- Registry status
- 22,054
- Enrollment target
NCT04974723 is a clinical trial that has completed, run by Radius Health. The registered enrollment target is 22,054 participants.
The verdict
NCT04974723 has completed, sponsored by Radius Health.
- COMPLETED
- Registry status
- 22,054 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the real-world effectiveness and cardiovascular safety of ABL compared with TPTD during the 18-month period after treatment initiation in propensity score (PS)-matched cohorts
Interventions
- DRUG Abaloparatide
- DRUG Teriparatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22,054 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2021-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04974723
The ClinicalTrials.gov registry entry for NCT04974723 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 22,054 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radius Health, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Abaloparatide is the first listed.
NCT04974723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04974723 about?
NCT04974723 is a clinical study titled "Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women". The purpose of the study is to evaluate the real-world effectiveness and cardiovascular safety of ABL compared with TPTD during the 18-month period after treatment initiation in propensity score (PS)-matched cohorts
What is the current status of trial NCT04974723?
This trial is currently completed. The enrollment target is 22,054 participants. The study started on 2021-07-01. Estimated completion is 2021-09-30.
What interventions are being tested in trial NCT04974723?
The interventions under investigation include: Abaloparatide (DRUG), Teriparatide (DRUG).
Who is sponsoring clinical trial NCT04974723?
This trial is sponsored by Radius Health, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.